1. Epigenetics
    Stem Cell/Wnt
    JAK/STAT Signaling
    Immunology/Inflammation
  2. JAK
    Interleukin Related
    IFNAR
  3. Deucravacitinib

Deucravacitinib (Synonyms: BMS-986165)

Cat. No.: HY-117287 Purity: 99.79%
Handling Instructions

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways.

For research use only. We do not sell to patients.

Deucravacitinib Chemical Structure

Deucravacitinib Chemical Structure

CAS No. : 1609392-27-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 209 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 209 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 190 In-stock
Estimated Time of Arrival: December 31
10 mg USD 350 In-stock
Estimated Time of Arrival: December 31
25 mg USD 550 In-stock
Estimated Time of Arrival: December 31
50 mg USD 850 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1350 In-stock
Estimated Time of Arrival: December 31
200 mg USD 2250 In-stock
Estimated Time of Arrival: December 31
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 6 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Deucravacitinib purchased from MCE. Usage Cited in: Cell Death Differ. 2021 Feb;28(2):748-763.

    Cells are treated with the allosteric TYK2 inhibitor BMS-986165 (TYK2 Inh.). BMS-986165 dose-dependently inhibits upregulation of CASP5 in response to LPS in U937 macrophages. CASP4 is constitutively expressed and not further upregulated by LPS.

    View All JAK Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways[1][2].

    IC50 & Target[1]

    Tyk2 JH2

    0.2 nM (IC50)

    JAK1 JH2

    1 nM (IC50)

    IL-12

     

    IL-23

     

    In Vitro

    Deucravacitinib (BMS-986165) is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism[1].
    Deucravacitinib maintains excellent potency in human and mouse whole blood (IC50s=13 and 100 nM, respectively) and shows no significant hERG inhibition in the flux assay (IC50>80 μM)[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    425.46

    Formula

    C₂₀H₁₉D₃N₈O₃

    CAS No.
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 37.5 mg/mL (88.14 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.3504 mL 11.7520 mL 23.5040 mL
    5 mM 0.4701 mL 2.3504 mL 4.7008 mL
    10 mM 0.2350 mL 1.1752 mL 2.3504 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% saline

      Solubility: 3.83 mg/mL (9.00 mM); Suspended solution; Need ultrasonic

    • 2.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (4.89 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (4.89 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.79%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Deucravacitinib
    Cat. No.:
    HY-117287
    Quantity:
    MCE Japan Authorized Agent: